Posted by Michael Wonder on 10 Dec 2024
Datopotamab deruxtecan granted breakthrough therapy designation in US for patients with previously treated advanced EGFR mutated non-small cell lung cancer
9 December 2024 - First breakthrough therapy designation for Daiichi Sankyo and AstraZeneca’s datopotamab deruxtecan based on TROPION-Lung05 Phase 2 trial and supported by data from TROPION-Lung01 Phase 3 trial.
Datopotamab deruxtecan has been granted breakthrough therapy designation in the US for the treatment of adult patients with locally advanced or metastatic epidermal growth factor receptor-mutated non-small cell lung cancer with disease progression on or after treatment with an EGFR tyrosine kinase inhibitor and platinum-based chemotherapy.
